1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“ Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections. This report provides information on the therapeutic development based on the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline Insights, 2014
Table of Contents
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Overview
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Pipeline Therapeutics
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics under Development by Companies
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Discontinued Products
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Products
- Companies Involved in Therapeutics Development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Assessment by Monotherapy Products
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Assessment by Combination Products
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Assessment by Route of Administration
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Assessment by Stage and Route of Administration
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Assessment by Molecule Type
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Assessment by Stage and Molecule Type
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics - Discontinued Products
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Assessment by Monotherapy Products
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Assessment by Combination Products
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Assessment by Route of Administration
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Assessment by Stage and Route of Administration
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Assessment by Molecule Type
- Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Asia-Pacific Animal Health Market - Forecast to 2021

Asia-Pacific Animal Health Market - Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The APAC animal health market is estimated to grow at a CAGR of 5.7% during the forecast period, to reach USD 20.25 billion by 2021 from USD 15.32 billion in 2016. Growth in this market can primarily be ...

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Silver sulfadiazine is an antibacterial drug used for making personal care products. Silver sulfadiazine is listed as the essential medicines by World Health Organization and is widely used as an antibiotic ...

Anti-infective Agents Market Analysis By Type (Antibacterial, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Antifungal, Azoles, Echinocandins, Polyenes, Antiviral) And Segment Forecasts To 2024

Anti-infective Agents Market Analysis By Type (Antibacterial, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Antifungal, Azoles, Echinocandins, Polyenes, Antiviral) And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The global anti-infective agents market is expected to reach over USD 111.4 billion by 2024 according to a new report by Grand View Research, Inc. The rising prevalence of infectious diseases such as HIV, ...

Global Feed Antibiotics Market

October 2016 $ 4250

Download Unlimited Documents from Trusted Public Sources

Related Market Segments :

Anti-Infective

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.